2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)thiophene CAS 1030825-20-7 Puritas ≥98.0% (HPLC) Imago Featured

2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)thiophene CAS 1030825-20-7 Munditia ≥98.0% (HPLC)

Description:

2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)thiophene

CAS: 1030825-20-7

Aspectus: Alba vel Off-White pulveris

Puritas: ≥98.0% (HPLC)

Medium API (CAS: 842133-18-0) in tractatione Type 2 diabete Mellito

Inquiry: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Manufacturer Supple intermedia:
4-Acidum Fluorophenylboronicum CAS: 1765-93-1
2-(4-Fluorophenyl)thiophene CAS: 58861-48-6
2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone CAS: 32384-65-9
5-Iodo-2-Methylbenzoicum Acidum CAS 54811-38-0
2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)thiophene CAS: 1030825-20-7
2-(4-Fluorophenyl) -5-[(5-iodo-2-methylphenyl)methyl]thiophene CAS: 898566-17-1
CAS: 842133-18-0
CAS: 928672-86-0

Chemical Properties:

Nomen chemicum	2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)thiophene
CAS Number	1030825-20-7
CATTUS Number	RF-PI234
Stock Status	In Stock, Productio Ascendite usque ad Centum chiliogrammata
Formulae hypotheticae	C18H14BrFS
M. Pondus	361.27
Liquescens punctum	103℃
Density	1.388
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba vel Off-White pulveris
Puritas / Analysis Methodus	≥98.0% (HPLC)
Damnum in Siccatio	≤1.00%
Requiesce in ignitio	≤0.50%
Metalla gravis	≤20ppm
Test Standard	Enterprise Standard
Consuetudinem	Medium API (CAS: 842133-18-0)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine & humore

commoda:

FAQ:

Applicatio:

Shanghai Ruifu Chemical Co., Ltd. est primarium fabricae et elit 2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)thiophene (CAS: 1030825-20-7) cum qualitate alta.Itmedium est typice in synthesi API (CAS: 461432-26-8).API (CAS: 461432-26-8) Novum medicamentum antidiabeticum a Bristol-Myers Squibb et AstraZeneca coniunctim elaboratum est, probatum ab Europaeis medicinis Agency (EMA) die 12 Novembris 2012. Etiam primum probatum SGLT2 inhibitorem curatio generis II diabete, optio magni momenti in tractatione diabete, et moderatio glycemica emendare adhibita est ad puritatem et exercitium adultorum cum speciebus II diabetis.